Results were similar when stratified by cooccurring medical conditions, with a 38% lower rate of opioid poisoning in those with type 2 diabetes and a semaglutide/tirzepatide-type prescription, 33% lower among those with obesity, and 35% lower among those with both type 2 diabetes and obesity
Tirzepatide (the main component in Mounjaro) is approved for the treatment of obesity, however, when used for weight control the company that makes it (Lilly) calls it Zepbound
I have had direct conversations on behalf of the Outsourcing Facilities Association and provided information to the administration both the FDA and HHS that shows that I believe that these products both GLP-1s are still in shortage, said Lee Rosebush, chairman of the trade association, which represents large-scale compounding pharmacies known as 503Bs
More than 70% of patients taking GLP-1 medications reported reduced alcohol cravings, a decreased desire to drink, a reduction in how much alcohol they drink per week, fewer drinks per drinking session, and reduced binge drinking compared to prior to starting treatment compared to the control group that was not taking GLP-1 medications
Tirzepatide (Mounjaro, Zepbound) is a GLP-1/GIP dual agonist
Changes to diet and exercise should also continue to be implemented alongside the use of these medications, for the most effective results
